A phase 3 study to evaluate the efficacy and safety of reparixin in severe COVID-19 pneumonia
G. Landoni (Milan, Italy), A. Voza (Milan, Italy), M. Puoti (Milan, Italy), N. Coppola (Naples, Italy), H. Akselrod (Washington D.C., United States), E. Gavioli (Boston, United States), E. Minnella (Milan, Italy), S. Toya (Milan, Italy), C. Marsiglia (Milan, Italy), F. Sergio (Milan, Italy), M. Allegretti (Milan, Italy), F. Mantelli (Milan, Italy)
Source: International Congress 2022 – COVID treatments
Session: COVID treatments
Session type: Thematic Poster
Number: 2596
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Landoni (Milan, Italy), A. Voza (Milan, Italy), M. Puoti (Milan, Italy), N. Coppola (Naples, Italy), H. Akselrod (Washington D.C., United States), E. Gavioli (Boston, United States), E. Minnella (Milan, Italy), S. Toya (Milan, Italy), C. Marsiglia (Milan, Italy), F. Sergio (Milan, Italy), M. Allegretti (Milan, Italy), F. Mantelli (Milan, Italy). A phase 3 study to evaluate the efficacy and safety of reparixin in severe COVID-19 pneumonia. 2596
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|